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Rifampin plays a crucial role in the treatment of staphylococcal implant-associated
infection, as it is the only antibiotic capable of eradicating Staphylococcus aureus
biofilms. However, the emergence of rifampin resistance strongly limits its use.
Combinatorial therapy of antibiotics and bacteriophages may represent a strategy
to overcome the resistance. Here, we evaluated the activity of staphylococcal
bacteriophage Sb-1 in combination with different antibiotics against the biofilms of
10 rifampin-resistant S. aureus clinical strains, including MRSA and MSSA. S. aureus
biofilms formed on porous glass beads were exposed to antibiotics alone or combined
with Sb-1 simultaneously or staggered (first Sb-1 for 24 h followed by antibiotic).
Recovered bacteria were detected by measuring growth-related heat production
at 37◦C (isothermal microcalorimetry) and the biofilm eradication was assessed by
sonication of beads and plating of the resulting sonication fluid. Minimum biofilm
eradication concentration (MBEC) was defined as the lowest concentration of antibiotic
required to kill all adherent bacteria, resulting in absence of growth after plating the
sonication fluid. Tested antibiotics presented high MBEC values when administered
alone (64 to > 1,024 µg/ml). The simultaneous or staggered combination of Sb-1
with daptomycin showed the highest activity against all MRSA biofilms, whereas the
exposure to Sb-1 with vancomycin showed no improved anti-biofilm activity. Staggered
administration of Sb-1 and flucloxacillin, cefazolin, or fosfomycin improved the antibiofilm
activity in four out of six MSSA, whereas simultaneous exposure exhibited similar or
lesser synergy. In conclusion, the combinatorial effect of Sb-1 and antibiotics enabled
to eradicate rifampin-resistant S. aureus biofilms in vitro.
Keywords: rifampin-resistant Staphylococcus aureus, bacterial biofilm, antibiotic–bacteriophage combination,
phage therapy, synergism, isothermal microcalorimetry
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INTRODUCTION
Staphylococcus aureus is one of the most common organisms
causing implant-associated infections, such as periprosthetic
joint infections (PJI), fracture-related infections (FRI), or
spinal implant-associated infections (Tong et al., 2015). The
pathogenesis involves the colonization of the device by
microorganisms leading to the formation of biofilm on the
surface of the implant, which makes the treatment of these
infections challenging. Optimal treatment implies debridement
and retention of the implant (in acute infections) or debridement
with removal of devitalized material and exchange of implant that
contain mature biofilm (in chronic infections) (Izakovicova et al.,
2019). In both clinical situations, eradication of the biofilm with
prolonged administration of biofilm-active antibiotics is required
(Sendi et al., 2008).
The treatment of implant-associated infections due to
S. aureus consists of initial intravenous antibiotic therapy,
including nafcillin, oxacillin, flucloxacillin, cefazolin, or
fosfomycin against methicillin-susceptible S. aureus (MSSA) and
vancomycin, daptomycin, or fosfomycin against methicillin-
resistant S. aureus (MRSA). In addition, rifampin is added
to treat staphylococcal infections in patients who undergo
debridement with retention or implant re-implantation in
one- or two-stage exchange (Berbari et al., 2020). Rifampin
should be co-administered with another active antibacterial
agent since, otherwise, rifampin resistance emerges rapidly
(Hoiby et al., 2015). With increased rifampin use, rifampin-
resistant staphylococcal strains are increasing worldwide,
representing an important concern. For example, in China,
the rifampin resistance in MRSA isolates increased from
15.5 to 50.2% within 4 years (2004–2008) (Wang C. et al.,
2019). Against rifampin-resistant mutants, rifampin has
no biofilm activity in vitro or in vivo (Croes et al., 2010).
Thus, alternative antimicrobial agents were investigated
(e.g., daptomycin, fosfomycin, and dalbavancin), but none
has shown biofilm activity in vivo. Another alternative is a
combination of antibiotics with lytic bacteriophages. Lytic
bacteriophages might exhibit rapid bactericidal activity,
biofilm degradative properties, and the ability to enhance
antibiotic activity (Tkhilaishvili et al., 2018) and are therefore
considered as alternative strategies combating bacterial infections
(Reardon, 2014).
Phage Sb-1 is one of the best characterized and fully
sequenced lytic staphylococcal phage developed as an anti-
infective therapy for human application by the Eliava Institute
in Georgia (Kutateladze and Adamia, 2008). Its genome
does not contain any bacterial virulence-associated genes,
making it suitable for antimicrobial therapy (Kvachadze et al.,
2011). Moreover, Sb-1 has been successfully used during
the former Soviet Union to treat S. aureus infections in
different patients (Sulakvelidze et al., 2001). However, there
are limited numbers of in vitro and in vivo studies published
regarding the activity of phage–antibiotic combination against
S. aureus strains. Our previous study showed a good synergistic
activity of phage Sb-1 and antibiotics against MRSA ATCC
43300 (Tkhilaishvili et al., 2018). In this study, we evaluated
the efficacy of different classes of antibiotics (vancomycin,
daptomycin, fosfomycin, gentamicin, flucloxacillin, cefazolin,
and rifampin) alone or in combination with Sb-1, by either
simultaneous or staggered application, against 10 rifampin-
resistant S. aureus (RRSA) clinical strains (four MRSA and six




Ten RRSA clinical isolates collected between 2015 and 2019
were included in this study. The clinical isolates were used
from the biobank collection, which is part of the prospective
institutional PJI cohort. The study was approved by the
institutional ethical committee (EA1/040/14) and was
conducted in accordance with the most recent iteration
of the Declaration of Helsinki. According to the ethical
approval, participants’ informed consent was waived, and all
data were pseudonymized. Moreover, MRSA ATCC 43300
and MSSA ATCC 29213 laboratory standard strains were
used in this study. Bacteria were stored at −80◦C using
a cryovial bead preservation system (Microbank; Pro-Lab
Diagnostics, Canada). The staphylococcal phage Sb-1 was
supplied by the Eliava Institute (Tbilisi, Georgia) and stored
at 4◦C.
Antimicrobial Agents and Susceptibility
Testing
Vancomycin (0.5 g, Hexal, Holzkirchen, Germany), daptomycin
(0.5 mg, Novartis Pharma Schweiz, Basel, Switzerland),
fosfomycin (5 g, InfectoPharm, Heppenheim, Germany),
gentamicin injectable solution (40 mg/ml, Ratiopharm,
Ulm, Germany), flucloxacillin (2 g, Stragen Pharma, Bad
Homburg, France), cefazolin (2 g, MIP Pharma, Blieskastel-
Niederwuerzbach, Germany), and rifampin (6 g, Sandoz
Pharmaceuticals, Steinhausen, Switzerland) were provided from
the respective manufacturers.
MIC for each antibiotic was determined by the broth
macrodilution assay (BMD) in brain heart infusion broth
(BHI; BD, Le Pont de Claix, France). An inoculum of
approximately 5 × 105 CFU/ml was used. Two fold
serial dilutions of each antibiotic were prepared in sterile
polystyrene round-bottom tubes to a final volume of 1 ml
in inoculated medium and incubated for 24 h at 37◦C.
The MIC was defined as the lowest concentration of
antibiotic that completely inhibited visible growth. BHI
broth medium was supplemented with calcium chloride
(40 µg/ml) and glucose 6-phosphate (25 µg/ml) when testing
daptomycin and fosfomycin, respectively. All experiments were
performed in triplicates.
The bacterial susceptibility to Sb-1 was evaluated in terms of
efficacy of plating (EOP) as previously described (Wang et al.,
2016). The EOP value was calculated as the ratio between the
plaque-forming units (PFU) on the tested clinical strains with
respect to the MRSA ATCC 43300 strain, defined as the host
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bacterium (EOP = phage titer on test bacterium/phage titer on
host bacterium). EOP values of 0.5–1 were ranked as “high”
efficiency; 0.2–0.5 as “medium” efficiency; 0.001–0.2 as “low”
efficiency; 0.0 was considered as not effective against the target
strain (Viazis et al., 2011).
Evaluation of Antibiofilm Activity by
Isothermal Microcalorimetry and
Sonication/Colony Counting
The antibiofilm activity of single antibiotics and phage–antibiotic
combination was determined by isothermal microcalorimetry
(IMC), as previously reported (Tkhilaishvili et al., 2018). Briefly,
biofilm formation was conducted by incubating porous glass
beads (ROBU, Hattert, Germany) in inoculated BHI media at
37◦C for 24 h. Beads where then washed (3x) with sterile
0.9% NaCl to remove planktonic cells and exposed to fresh
BHI containing antibiotic. After 24 h of incubation at 37◦C,
beads were rinsed (3x) with 0.9% saline and inserted in
microcalorimetry ampoules containing 3 ml of fresh BHI
and introduced into the calorimeter. The minimum biofilm
bactericidal concentration (MBBC) was defined as the lowest
concentration of antibiotic that led to the absence of heat
production after 48 h of incubation at 37◦C. The effect of
combined treatment (antibiotic + Sb-1) was evaluated by either
simultaneous or staggered application, of 106 PFU/ml Sb-1 phage
and sub-MBBC concentrations of antibiotics. By simultaneous
application, biofilms were exposed to antibiotics and Sb-1 during
24 h at 37◦C. By staggered application, biofilms were exposed
first to Sb-1 for 24 h and then to antibiotic for a further 24 h
at 37◦C. Evaluation of a staggered application of antibiotic
followed by phage was discarded based on the unfavorable
results observed in previous studies (Kumaran et al., 2018;
Tkhilaishvili et al., 2018).
For samples where no heat production was detected,
the complete biofilm eradication was determined by CFU
counting of the sonicated beads after the microcalorimetric
assay, and the minimum biofilm-eradicating concentration
(MBEC) was defined as the lowest concentration of antibiotic
required to kill all adherent bacteria, resulting in absence of
any growth after plating of the sonication fluid (detection
limit: <20 CFU/ml) (Gonzalez Moreno et al., 2019). All
experiments were performed in triplicates.
The effect of phage–antibiotic combinations against biofilms
was assessed as in a previous study (Ryan et al., 2012),
determining the MBECphage/MBECalone ratio, where MBECphage
corresponds to the obtained MBEC value of an antibiotic
tested in combination with the phage, and the MBECalone
represents the obtained MBEC value of the same antibiotic
when tested alone. Synergy was defined as a ratio ≤ 0.25,
which correlated with a reduction of more than 2xMBECalone.
We combined and tested only concentrations of antibiotic
that could reveal a synergistic effect with Sb-1 based on
the MBEC values of the single antibiotic to be combined
(antibiotics presenting an MBECalone > 1,024 µg/ml were tested
in combination with Sb-1 at increasing concentrations up to
256 µg/ml).
RESULTS
Bacterial Susceptibility to Conventional
Antibiotics and Sb-1
The antimicrobial activity of antibiotics against planktonic and
biofilm S. aureus was determined by BMD and by plating of
sonication fluid, respectively. The obtained MIC and MBEC
values are summarized in Table 1. Additionally, the MBBC values
assessed by IMC and the effect of Sb-1 against the biofilm of both
ATCC strains are shown in Supplementary Figures S1, S2.
Both ATCC strains were susceptible to all antibiotics
according to the EUCAST breakpoints (EUCAST, 2020), except
for MRSA ATCC 43300 that was resistant to gentamicin. The
10 RRSA strains were susceptible to all antibiotics, besides
for MRSA4, resistant to fosfomycin, and MSSA5, resistant
to gentamicin. All tested strains were susceptible to higher
concentrations of antibiotics (ranging from 64 to > 1,024 µg/ml)
when grown as biofilms if compared to the MIC values obtained
for planktonic bacteria.
The antibiofilm activity of different antibiotics against
the ATCC strains was evaluated by monitoring for 48 h
the heat produced by biofilm bacteria still viable on the
beads (after the exposure to the antibiotics) re-inoculated
in fresh medium (Supplementary Figure S1). On the one
hand, MRSA ATCC 43300 was susceptible to daptomycin and
rifampin at concentrations of 128 and 256 µg/ml, respectively,
whereas MSSA ATCC 29213 showed susceptibility to gentamicin
and rifampin at concentrations of 512 and 256 µg/ml,
correspondingly. The rest of the antibiotics, tested up to
1,024 µg/ml, showed no inhibition of heat flow production on the
corresponding strain, indicating no antibiofilm activity despite
the presence of high concentrations of antibiotic.
The exposure of the biofilm from both ATCC strains
during 24 h to Sb-1 revealed a distinct effect on each strain.
A remarkable reduction but not complete inhibition of the heat-
flow production compared to the heat-flow produced by the
growth control could be observed with the treated MRSA strain,
whereas almost no difference between control and treated sample
was observed for MSSA (Supplementary Figure S2). All S. aureus
strains were susceptible to Sb-1 infection, showing EOP ratios
ranging from 0.3 to 0.9 (Supplementary Table S1), indicative of
a high lytic activity (EOP 0.5–1) of Sb-1 against most strains.
Evaluation of Phage–Antibiotic
Combinations Against ATCC Strains
The synergistic effect of simultaneous (Figure 1) and staggered
(Figure 2) phage–antibiotic combinations against biofilm of
both ATCC strains was investigated by IMC. Additionally,
the presence of viable bacteria attached to the beads after
calorimetry of those samples showing no heat production was
evaluated by colony counting after bead sonication and plating
of the sonication fluids. The obtained MBEC values as well
as the calculated MBECphage/MBECalone ratios are summarized
in Table 2.
Among all simultaneously tested phage–antibiotic
combinations against MRSA ATCC 43300, only the exposure of
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TABLE 1 | Antimicrobial susceptibility of planktonic (MIC) and biofilm (MBEC) Staphylococcus aureus strains determined by conventional broth macrodilution assay and
sonication/colony-counting.
Antibiotic VAN DAP FOF GEN RIF
MRSA strains MIC MBEC MIC MBEC MIC MBEC MIC MBEC MIC MBEC
MRSA ATCC 43300 1 >1,024 0.5 128 8 >1,024 64(R) >1,024 0.008 256
MRSA1 1 >1,024 0.5 64 4 >1,024 0.5 256 32(R) >1,024
MRSA2 2 >1,024 1 128 4 >1,024 0.5 512 1(R) >1,024
MRSA3 1 >1,024 0.5 64 128(R) >1,024 0.5 512 32(R) >1,024
MRSA4 1 >1,024 1 128 4 >1,024 0.5 >1,024 4(R) >1,024
Antibiotic FLU CFZ FOF GEN RIF
MSSA strains MIC MBEC MIC MBEC MIC MBEC MIC MBEC MIC MBEC
MSSA ATCC 29213 0.5 >1,024 0.5 >1,024 4 >1,024 1 512 0.016 256
MSSA1 0.25 1,024 0.25 >1,024 16 >1,024 0.5 512 1(R) >1,024
MSSA2 0.5 1,024 0.5 >1,024 4 >1,024 0.5 512 32(R) >1,024
MSSA3 0.5 1,024 0.5 >1,024 8 >1,024 0.5 >1,024 32(R) >1,024
MSSA4 0.25 >1,024 0.25 >1,024 8 >1,024 0.5 >1,024 1(R) >1,024
MSSA5 0.5 512 0.5 >1,024 16 >1,024 8(R) >1,024 2(R) >1,024
MSSA6 0.5 >1,024 0.25 >1,024 4 >1,024 0.5 1,024 1(R) >1,024
MIC and MBEC concentration values are expressed in µg/ml. VAN, vancomycin; DAP, daptomycin; FOF, fosfomycin; GEN, gentamicin; RIF, rifampin; FLU, flucloxacillin;
CFZ, cefazolin; R, resistance against the antibiotic according to EUCAST.
FIGURE 1 | Microcalorimetry analysis of methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (upper row) and methicillin-susceptible S. aureus (MSSA)
ATCC 29213 (bottom row) biofilms treated simultaneously with Sb-1 phage and sub-minimum biofilm bactericidal concentration (MBBC) concentrations of
antibiotics. Each curve shows the heat produced by viable bacteria present in the biofilm after 24 h of phage–antibiotic treatment. Numbers represent concentrations
(in µg/ml) of vancomycin (VAN), daptomycin (DAP), fosfomycin (FOF), gentamicin (GEN), rifampin (RIF), flucloxacillin (FLU), and cefazolin (CFZ). Circled values
represent the MBBC, defined as the lowest antimicrobial concentration leading to absence of bacterial regrowth after 48 h. GC, growth control; NC, negative control.
Data of a representative experiment are reported.
biofilm to Sb-1 and sub-MBBC concentrations of daptomycin
or rifampin showed a synergistic effect. In contrast, the
strongest synergistic effect was observed by staggered
exposure of MRSA ATCC 43300 to Sb-1 and sub-MBBC
concentrations of vancomycin or daptomycin, showing the
lowest MBECphage/MBECalone ratios, followed by fosfomycin
and rifampin (Table 2), whereas no synergistic effect was
observed with gentamicin, possibly due to the resistance profile
of this strain toward gentamicin.
No synergistic effect was observed by the phage–antibiotic
combinations against MSSA ATCC 29213, either simultaneous
or staggered. Overall, when MRSA ATCC 43300 biofilm was
first exposed to Sb-1 during 24 h prior to the exposure to
sub-MBBC concentrations of antibiotics, a higher delay and/or
reduction of heat-flow production was obtained compared
to the heat-flow produced when biofilm was exposed to
simultaneous phage/antibiotic combinations at the same
antibiotic concentrations, whereas this effect was not as





The ability of phage–antibiotic combinations to eradicate the
biofilm of 10 clinical rifampin-resistant MRSA and MSSA
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FIGURE 2 | Microcalorimetry analysis of MRSA ATCC 43300 (upper row) and MSSA ATCC 29213 (bottom row) biofilms after staggered application of Sb-1 phage
for 24 h followed by 24 h exposure to sub-MBBC concentrations of antibiotics. Each curve shows the heat produced by viable bacteria present in the biofilm after
phage–antibiotic treatment. Numbers represent concentrations (in µg/ml) of vancomycin (VAN), daptomycin (DAP), fosfomycin (FOF), gentamicin (GEN), rifampin
(RIF), flucloxacillin (FLU), and cefazolin (CFZ). Circled values represent the MBBC, defined as the lowest antimicrobial concentration leading to absence of bacterial
regrowth after 48 h. GC, growth control; NC, negative control. Data of a representative experiment are reported.
TABLE 2 | Antibiofilm effects of simultaneous or staggered phage–antibiotic combinations.
Antibiotic Simultaneous exposure Staggered exposure
MBEC (µg/ml) Ratio (interpretation) MBEC (µg/ml) Ratio (interpretation)
MRSA ATCC 43300
VAN >256 > 0.25 (NS)a 16 0.015 (S)
DAP 32 0.25 (S) 2 0.015 (S)
FOF >256 > 0.25 (NS)a 32 0.031 (S)
GEN >256 > 0.25 (NS)a >256 > 0.25 (NS)a
RIF 64 0.25 (S) 8 0.031 (S)
MSSA ATCC 29213
FLU >256 > 0.25 (NS)a >256 > 0.25 (NS)a
CFZ >256 > 0.25 (NS)a >256 > 0.25 (NS)a
FOF >256 > 0.25 (NS)a >256 > 0.25 (NS)a
GEN 256 0.5 (NS) >256 > 0.25 (NS)a
RIF 128 0.5 (NS) 128 0.5 (NS)
VAN, vancomycin; DAP, daptomycin; FOF, fosfomycin; GEN, gentamicin; RIF, rifampin; FLU, flucloxacillin; CFZ, cefazolin; S, synergism; NS, no synergism. aMBEC value
above 1/4xMBECalone (considering MBECalone equal to 1,024 µg/ml), thus MBECphage/MBECalone ratio is interpreted as >0.25 (NS).
strains was directly evaluated by sonication/colony-counting as
described previously, and results are shown in Table 3.
Among four MRSA isolates, a synergistic effect was observed
for all strains after exposure to Sb-1/daptomycin combination
(either simultaneously or staggered), in three strains (75%)
when exposure to Sb-1/gentamicin staggered combination and
in two (50%) strains exposed to staggered Sb1/fosfomycin or
to simultaneous Sb-1/gentamicin combination. No synergistic
effect was observed when the biofilm of tested clinical
strains was exposed to either simultaneous or staggered Sb-
1/vancomycin combination, in contrast to the finding with
MRSA ATCC 43300 strain.
Among six MSSA isolates, synergistic effect was observed
in four strains (67%) after staggered exposure to Sb-
1/flucloxacillin or to Sb-1/cefazolin, and in three strains
(50%) with simultaneous Sb-1/flucloxacillin combination. Only
staggered but not simultaneous Sb-1/fosfomycin combination
revealed a synergistic effect against four strains (67%), whereas
simultaneous or staggered Sb-1/gentamicin combination
showed synergism against three strains (50%). None of the
tested simultaneous or staggered phage/antibiotic combinations
presented an improvement in the antimicrobial activity
compared to the action of each antimicrobial agent alone
against MSSA5 biofilm.
Moreover, no synergism was found with Sb-1 and rifampin
combination against MRSA or MSSA (Supplementary Table S2).
DISCUSSION
Biofilm formation on the device surface is the key occurrence in
the pathogenesis of implant-associated infections, requiring the
use of biofilm-active antibiotics (Davidson et al., 2019). Rifampin
emerged about three decades ago as an antibiofilm antibiotic
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TABLE 3 | Antibiofilm effects of simultaneous (MBECSIM ) or staggered (MBECSTA) phage–antibiotic combinations against clinical strains.
Antibiotic VAN DAP FOF GEN
MRSA strains MBECSIM MBECSTA MBECSIM MBECSTA MBECSIM MBECSTA MBECSIM MBECSTA
MRSA1 >256 (NS)a >256 (NS)a 8 (0.125, S) 8 (0.125, S) >256 (NS)a 64 (0.06, S)b 64 (0.25, S) 64 (0.25, S)
MRSA2 >256 (NS)a >256 (NS)a 16 (0.125, S) 16 (0.125, S) >256 (NS)a 256 (0.25, S)b 256 (0.5, NS) 64 (0.125, S)
MRSA3 >256 (NS)a >256 (NS)a 16 (0.25, S) 16 (0.25, S) >256 (NS)a >256 (NS)a 128 (0.25, S) 64 (0.125, S)
MRSA4 >256 (NS)a >256 (NS)a 16 (0.125, S) 16 (0.125, S) >256 (NS)a >256 (NS)a >256 (NS)a >256 (NS)a
Antibiotic FLU CFZ FOF GEN
MSSA strains MBECSIM MBECSTA MBECSIM MBECSTA MBECSIM MBECSTA MBECSIM MBECSTA
MSSA1 128 (0.125, S) 64 (0.006, S) >256 (NS)a 256 (0.25, S)b >256 (NS)a >256 (NS)a 128 (0.25, S) 128 (0.25, S)
MSSA2 256 (0.25, S) 32 (0.003, S) >256 (NS)a 128 (0.125, S)b >256 (NS)a 64 (0.006, S)b 128 (0.25, S) 128 (0.25, S)
MSSA3 256 (0.25, S) 32 (0.003, S) >256 (NS)a 256 (0.25, S)b >256 (NS)a 256 (0.25, S)b >256 (NS)a >256 (NS)a
MSSA4 >256 (NS)a >256 (NS)a >256 (NS)a >256 (NS)a >256 (NS)a 256 (0.25, S)b >256 (NS)a >256 (NS)a
MSSA5 256 (0.5, NS) 256 (0.5, NS) >256 (NS)a >256 (NS)a >256 (NS)a >256 (NS)a >256 (NS)a >256 (NS)a
MSSA6 >256 (NS)a 32 (0.003, S)b >256 (NS)a 16 (0.015, S)b >256 (NS)a 32 (0.003, S)b 256 (0.25, S) 256 (0.25, S)
MBEC concentration values are expressed in µg/ml. In brackets is shown the ratio value followed by the ratio interpretation. VAN, vancomycin; FLU, flucloxacillin; DAP,
daptomycin; CFZ, cefazolin; FOF, fosfomycin; GEN, gentamicin; S, synergism; NS, no synergism. aMBEC value above 1/4xMBECalone (considering MBECalone equal to
1,024 µg/ml), thus MBECphage/MBECalone ratio is interpreted as >0.25 (NS). bMBECalone considered equal to 1,024 µg/ml for MBECphage/MBECalone ratio calculations.
against S. aureus orthopedic implant-associated infections
(Zimmerli and Sendi, 2019), presenting good penetration and
bioavailability in osteo-articular tissue (Sendi and Zimmerli,
2017). In this study, we investigated alternatives to rifampin for
the treatment of implant-associated infections caused by RRSA.
Phage efficacy has been described to be influenced by host
specificity, among several other factors (Ly-Chatain, 2014). In
our study, Sb-1 showed high killing effect against most tested
strains, but still a complete biofilm eradication with the phage
alone was not achieved, possibly due to the establishment of
an equilibrium between virus and host, as reported earlier
(Głowacka-Rutkowska et al., 2019), what might be prevented
with the addition of antibiotics.
The phage–antibiotic combinations tested in our study were
selected based on the methicillin-resistant profile of the S. aureus
isolates, as usually done in the clinical setting (Berbari et al.,
2020). Hence, in addition to testing fosfomycin and gentamicin
against all strains, daptomycin and vancomycin were selected
for testing on MRSA strains, while flucloxacillin and cefazolin
were selected for testing on MSSA strains. For the evaluation
of phage–antibiotic combinations, a fixed value of 1,024 µg/ml
was considered for the calculation of the MBECphage/MBECalone
ratios for samples with MBECalone > 1,024 µg/ml. It should
be noted that, by this approach, some combinations that were
interpreted as not synergistic could turn out to have a synergistic
effect when testing higher MBEC values. However, the observed
positive synergistic effects of phage–antibiotic combinations
with our experimental setup are certain and usually presenting
considerably lower MBEC values compared to the MBEC values
of single antibiotics.
The determination of the EOP ratios is a frequent test to
identify phages suitable for phage therapy (Khan Mirzaei and
Nilsson, 2015). In our study, however, we did not observe a
correlation between the EOP rank and the antibiofilm activity of
the phage against a specific strain. For instance, Sb-1 showed low
efficacy against MSSA ATCC 29213 biofilm with no synergistic
effect in combination with antibiotics despite a high EOP
rank, but Sb-1 in combination with daptomycin resulted in a
synergistic effect against MRSA3 and MRSA4 although showing
lower EOP ratios on these strains. Thus, in the context of using
phages to control bacterial biofilms, the determination of the
EOP ratios should not be misinterpreted toward a correlation
to efficiency against biofilms. The nature of the biofilm matrix
can differ among strains, ultimately affecting the bioavailability
and/or function of an antimicrobial, as suggested by Bauer
and coworkers (Bauer et al., 2013), who evaluated antibiotic
activity on young and mature MSSA and MRSA biofilms and
observed that, besides biofilm maturity, the bacterial strain clearly
influenced antibiotic activity.
The order of administration when combining antibiotics and
phages has been shown to play a key role for a synergistic
antimicrobial effect (Dickey and Perrot, 2018; Kumaran et al.,
2018). We observed a synergistic effect when Sb-1 was combined
with fosfomycin or cefazolin by staggered application but not
when these antibiotics and Sb-1 were applied simultaneously.
Moreover, the pre-exposure to Sb-1 followed by flucoxacillin
eradicated the biofilm at lower antibiotic concentrations
compared to simultaneous application. These findings indeed
seem to indicate that exposure of biofilms first to phage followed
by antibiotics is the most effective way to eradicate them. Previous
studies have shown the benefit of the staggered application when
combining antibiotics and phages (Tkhilaishvili et al., 2018),
while a simultaneous exposure could result in hindering their
antibiofilm efficacy, possibly due to antagonistic modes of action
(e.g., antibiotics interfering with the bacterial DNA replication
process) or due to the killing of host bacteria – which is essential
for phage production – by the antibiotic (Chaudhry et al., 2017;
Kumaran et al., 2018; Akturk et al., 2019).
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On the other hand, other than with the MRSA ATCC
strain, combining Sb-1 and daptomycin or vancomycin against
rifampin-resistant MRSA strains exhibited the same outcome
independently of the order of administration. In a previous study
by Dickey and Perrot (2018), the authors also showed that a
simultaneous treatment of S. aureus biofilm with daptomycin
and phage was as effective as sequential treatment. Moreover,
they showed an antagonistic effect when combining phage
and vancomycin. Considering that the wall teichoic acid from
the bacterial cell wall is the primary staphylococcal phage
receptor (Azam and Tanji, 2019) and that vancomycin has
a unique mechanism of action inhibiting cell wall synthesis
(Watanakunakorn, 1984), it is conceivable that phage infection
was negatively affected by the vancomycin impact on the
bacterial cell wall. Daptomycin action disrupting the bacterial
cell membrane structure seems to have a lower interference
with phage action. As shown also by Dickey and Perrot, the
simultaneous application of phage and daptomycin at 10xMIC
allowed phage growth, whereas most antibiotics tested in their
study at 10xMIC either prevented phage growth (ciprofloxacin,
vancomycin, and tetracyclin) or led to massive decreases
in phage density (gentamicin, erythromycin, and linezolid)
(Dickey and Perrot, 2018).
Generally, vancomycin is recommended for the treatment
of MRSA implant-associated infections (Paiva and Eggimann,
2017), yet a high rate of vancomycin treatment failure in
vancomycin-susceptible MRSA infections has been reported
(Dombrowski and Winston, 2008; Abdelhady et al., 2013). This
observation correlates with our findings showing the inefficiency
of treating biofilms of clinical strains with vancomycin alone
or combined with Sb-1. The low efficacy of vancomycin
against staphylococcal biofilms could be due to a reduced
biofilm penetration, a reduced concentration of free vancomycin
being sequestrated by S. aureus on peptidoglycan layers, or
a stimulation of biofilm formation by low concentrations of
vancomycin (Broussou et al., 2018). Conversely, daptomycin has
shown a superior efficacy against bone and joint infections caused
by MRSA (Chang et al., 2017; Telles et al., 2019). The consistent
synergistic effect observed with Sb-1/daptomycin combination
against all tested rifampin-resistant MRSA strains in our study,
together with the good biofilm penetration properties (Ozturk
et al., 2016) and in vitro activity against stationary-phase bacteria
inside the biofilm (Smith et al., 2009), makes daptomycin a
promising candidate for combinatorial therapy.
Another promising therapeutic approach based on our results
was found by the combination of Sb-1 with flucloxacillin
for the eradication of rifampin-resistant MSSA strains, where
there was a remarkable reduction in the MBEC values, and
MBECphage/MBECalone ratios as low as 0.003, could be observed
after staggered phage-antibiotic administration against 67% of
the strains. Analysis on the production of type A beta-lactamase
by MSSA strains, responsible for cefazolin hydrolysis (Nannini
et al., 2009), could bring insights on the lower antibiofilm efficacy
of cefazolin compared to flucloxacillin.
Low MBECphage/MBECalone ratios (ranging from 0.003 to
0.06) were also observed with staggered administration of
Sb-1 with fosfomycin. Fosfomycin has been shown to act
synergistically with other antibiotics against biofilms of different
bacterial species, including MRSA, in part probably because of
its broad-spectrum bactericidal activity (Chai et al., 2016; Wang
L. et al., 2019). In addition, favorable characteristics associated
to fosfomycin include the ability to break up biofilms and
enhance the permeability of other antimicrobials and a presumed
immunomodulatory effect (Mihailescu et al., 2014).
Previous studies revealed synergistic effects by combining
phage with an antibiotic for which the bacteria strain was
resistant (Liu et al., 2020). In our study, however, the use of Sb-1
in combination with rifampin against biofilms of RRSA strains,
as well as Sb-1/fosfomycin and Sb-1/gentamicin combinations
against MRSA3 and MRSA ATCC 43300, respectively, did not
reveal an improved anti-biofilm effect.
When trying to draw conclusions or make clinical
extrapolations, it is important to consider the small number of
tested strains in our study. We aimed to provide the first original
data on the combinatorial effect of Sb-1 and different antibiotics
to eradicate RRSA biofilms in vitro. Our work highlights that
findings obtained testing ATCC strains may differ from the
outcome with clinical isolates, but also among the different
strains, implying that selecting an appropriate phage–antibiotic
combinatorial therapy will be highly dependent on the strain
causing the infection as well as on the specific antibiofilm efficacy
of the phage, more than its lytic spectrum. Moreover, there is
substantial evidence that many antibiotics can interfere with
phage infection activity—especially at concentrations exceeding
measured minimum inhibitory concentrations—and thus with
phage primary pharmacodynamic properties. Hence, further
preclinical and clinical studies are essential to support the
development of phage/antibiotic combination therapy with
particular isolates. Factors that point toward a more personalized
approach for the successful treatment of antibiotic-resistant
implant-associated infections.
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